The upfront use of docetaxel chemotherapy or treatments with androgen receptor axis‐targeted (ARAT) agents in addition to ADT is a recent trend resulting in prolonged survival in metastatic PCa patients characterized as having castration‐sensitive and high‐risk cancer.2 This evidence concerns the gene AR and posterior cortical atrophy.